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A New HCC Model Induced by Co-overexpression FGF19 and Met in Mice
Junyan Tao1,2, Morgan Preziosi1,2, Sucha Singh1.2, Xin Chen4,5, Satdarshan P. S.
Monga1,2,3
1Department

of Pathology, 2Pittsburgh Liver Research Center, and 3Department of

Medicine, University of Pittsburgh, School of Medicine and University of Pittsburgh
Medical Center, Pittsburgh, PA; Pittsburgh, PA;
4Department
5Liver

of Bioengineering and Therapeutic Sciences and

Center, University California, San Francisco, CA

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths
worldwide. Sorafenib is the only targeted therapy approved for HCC. Thus, developing
useful animal models may shed light on the biology of HCC tumor and provide a
platform to evaluate the potential therapeutic agents.
In the current study, we found FGF19 and cMet work synergistically to induce tumor after
13 weeks post co-delivery FGF19 and cMet to the mice hepatocytes using the sleeping
beauty transposon/transposase system via hydrodynamic tail vein injection. H&E
staining showed the tumor is HCC, meanwhile, the immunochemistry staining results
showed that Glycogen synthase (GS) genitive and cell cycle D1(CCND1) was
upregulated in the tumor area, ki67 also increased in the tumor nodule. pERK and
pmTOR was also activated in the tumor areas by IHC staining.
Such data showed mTOR and ERK pathway might be required for HCC induced by
FGF19/Met. The molecular mechanisms and target therapy could be carried based on
this model in the near future, including single gene target and combination target
therapy.
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